These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 16950824)

  • 1. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro.
    Wade MM; Zhang Y
    J Antimicrob Chemother; 2006 Nov; 58(5):936-41. PubMed ID: 16950824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].
    Chen ZF; Huang Q; Li YY; Zhang Y; Ren Y; Li KS; Fu ZJ; Xu SQ
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 May; 30(5):359-62. PubMed ID: 17651643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron enhances the antituberculous activity of pyrazinamide.
    Somoskovi A; Wade MM; Sun Z; Zhang Y
    J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
    Huang Q; Chen ZF; Li YY; Zhang Y; Ren Y; Fu Z; Xu SQ
    Chemotherapy; 2007; 53(5):338-43. PubMed ID: 17785970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
    Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
    J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The curious characteristics of pyrazinamide: a review.
    Zhang Y; Mitchison D
    Int J Tuberc Lung Dis; 2003 Jan; 7(1):6-21. PubMed ID: 12701830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
    Yamamoto S; Toida I; Watanabe N; Ura T
    Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide.
    Gu P; Constantino L; Zhang Y
    J Med Microbiol; 2008 Sep; 57(Pt 9):1129-1134. PubMed ID: 18719183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
    Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
    J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
    Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
    Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on the effect of antituberculosis agents against tubercle bacilli in the resting state, using streptomycin-dependent strain (18-b). I. Studies in vitro].
    Ota Y
    Kekkaku; 1971 Aug; 46(8):295-301. PubMed ID: 4328204
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
    Bergmann KE; Cynamon MH; Welch JT
    J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
    Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
    Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages.
    Heifets L; Higgins M; Simon B
    Int J Tuberc Lung Dis; 2000 Jun; 4(6):491-5. PubMed ID: 10864178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations.
    Heifets L; Lindholm-Levy P
    Am Rev Respir Dis; 1992 May; 145(5):1223-5. PubMed ID: 1586071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil.
    Barco P; Cardoso RF; Hirata RD; Leite CQ; Pandolfi JR; Sato DN; Shikama ML; de Melo FF; Mamizuka EM; Campanerut PA; Hirata MH
    J Antimicrob Chemother; 2006 Nov; 58(5):930-5. PubMed ID: 16971417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
    Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
    Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
    Aragón LM; Garrigó M; Moreno C; Español M; Coll P
    J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Specificity of antituberculous action in vitro of pyrazine-2-carboxylic acid derivatives].
    Pavlov EP
    Probl Tuberk; 1971; 49(7):76-9. PubMed ID: 5004351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.